Lawmakers press Trump administration to revisit rule that could curb cross-border drug imports
A growing bloc of congressional members is urging the Trump administration to reconsider a new customs rule that would make importing prescription drugs from Canada and other countries more costly and complex.
Congressional representatives are intensifying calls for the Trump administration to halt a pending customs rule slated for implementation next month. The rule would force medicines shipped from abroad to clear customs through a licensed broker and secure a financial entry bond, creating new costs and procedural hurdles. Advocates for the change warn that the measure could disrupt a long-standing practice of U.S. patients turning to Canadian and other foreign pharmacies for lower-priced prescriptions.
Although the regulation is presented as a safety safeguard, opponents contend it will inflate drug costs and restrict access for those dependent on imported medicines. Under existing statutes, personal importation of most prescription drugs remains prohibited unless specific FDA approvals are in place. The debate reflects broader tensions over drug pricing, safety, and cross-border trade.
Why it matters
The rule could raise drug costs and limit access to affordable medicines for U.S. patients.
In this story
